Description
The BD Leucocount™ kit consists of BD Leucocount™ reagent (propidium iodide fluorescent dye) and BD Trucount™ tubes and is intended for use with the BD FACSCalibur™, BD FACSort™, BD FACScan™, and BD FACSVia™ flow cytometer systems, or for a flow cytometer equipped with a 488-nm argon ion laser able to threshold on FL2, for enumerating residual white blood cells (rWBCs) in leucoreduced blood products.
| Resources & Tools | ||||||
|---|---|---|---|---|---|---|
| SpectrumViewer | Download MSDS | |||||
Preparation and Storage
• Store BD Leucocount reagent at 2°C– 8°C. Do not use after the expiration date shown on the label. • Avoid unnecessary exposure of the reagent to light.
• Do not freeze the reagents or expose them to direct light during storage or incubation with cells. Keep the reagent vials dry.
• Store BD Trucount tubes in their original foil pouch at 2°C–25°C. To avoid potential condensation, open the pouch only after it has reached room temperature and carefully reseal the pouch immediately after removing a tube. Examine the desiccant each time you open the pouch. If the desiccant has turned from blue to lavender, discard the remaining tubes. Use tubes within 1 hour after removal from the foil pouch. Once the pouch has been opened, the tubes are stable for 1 month. Do not use beyond the expiration date indicated on the packaging.
- Protection of Laboratory Workers fromOccupationally Acquired Infections; ApprovedGuideline—Third Edition. Wayne, PA: Clinical andLaboratory Standards Institute; 2005. CLSIdocument M29-A3.
- Bull BS, Breton-Corius J. Morphology of the erythron. In: Beutler E, Lichtman MA, Coller BS, Kripps TJ, eds. Williams Hematology. 5th ed. New York, NY: McGraw-Hill, Inc; 1995:349.
- Center for Biologics Evaluation and Research. Recommendations and Licensure Requirements for Leukocyte-Reduced Blood Products. Rockville, MD: Food and Drug Administration; 1996.
- Centers for Disease Control. Perspectives in disease prevention and health promotion update: universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus, and other bloodborne pathogens in health-care settings. MMWR. 1988;37:377-388.
- de Graan-Hentzen YCE, Gratama JW, Mudde GC, et al. Prevention of primary cytomegalovirus infection in patients with hematologic malignancies by intensive white cell depletion of blood products. Transfusion. 1989;29:757-760.
- Sniecinski I, O"Donnell MR, Nowicki B, Hill LR. Prevention of refractoriness and HLAalloimmunization using filtered blood products. Blood. 1988;71:1402-1407.
- Wenz B, Gurtlinger K, O"Toole A, Dugan E. Preparation of granulocyte-poor red blood cells by microaggregate filtration. A simplified method to minimize febrile transfusion reactions. Vox Sang. 1980;39:282-287.
